Katharine Knobil
2020
In 2020, Katharine Knobil earned a total compensation of $1.5M as Former CMO & Head of R&D at Kaleido Biosciences, a 20% increase compared to previous year.
Compensation breakdown
| Bonus | $75,668 |
|---|---|
| Non-Equity Incentive Plan | $157,590 |
| Option Awards | $805,820 |
| Salary | $450,000 |
| Other | $12,524 |
| Total | $1,501,602 |
Knobil received $805.8K in option awards, accounting for 54% of the total pay in 2020.
Knobil also received $75.7K in bonus, $157.6K in non-equity incentive plan, $450K in salary and $12.5K in other compensation.
Rankings
In 2020, Katharine Knobil's compensation ranked 6,812th out of 13,090 executives tracked by ExecPay. In other words, Knobil earned more than 48.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,812 out of 13,090 | 48th |
Division Manufacturing | 2,838 out of 5,621 | 50th |
Major group Chemicals And Allied Products | 1,148 out of 2,254 | 49th |
Industry group Drugs | 989 out of 1,954 | 49th |
Industry Biological Products, Except Diagnostic Substances | 237 out of 411 | 42nd |
Source: SEC filing on May 5, 2021.
Knobil's colleagues
We found three more compensation records of executives who worked with Katharine Knobil at Kaleido Biosciences in 2020.